Inside EDQM: Active Ingredient Inspection and Certification - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Inside EDQM: Active Ingredient Inspection and Certification
The EDQM inspection program helps to ensure the quality of APIs on the European market.


Pharmaceutical Technology
Volume 10, Issue 34, pp. 80, 84

Inspection outcomes

When an inspection outcome is positive, a GMP certificate is granted by the inspector from the competent authority of the EU or EEA to the manufacturer. Additionally, EDQM issues an attestation stating that the company has been inspected and found compliant with GMP and the CEP application dossier.

In the case of major deficiencies or in case of a refusal by the company to be inspected, actions may be taken on the corresponding CEPs or CEP applications (e.g., suspension or cancellation of the CEP, closure of ongoing CEP applications). The inspector issues a statement of noncompliance which is also distributed to the appropriate competent authorities. Suspensions and cancellations of CEPs are reported to all concerned authorities so that action regarding related marketing authorization(s) can be taken. Suspensions and cancellations are published on EDQM's website. A suspension may only be lifted after the company takes satisfactory corrective actions and after a re-inspection confirms the implementation of those actions.

International collaboration

EDQM is involved in the international pilot project coordinated by the European Medicines Agency to exchange information on API inspections with the US Food and Drug Administration and Australia's Therapeutic Goods Administration (TGA). EDQM has also carried out joint inspections with the World Health Organization (WHO) for API manufacturers covered by CEPs which were also within the scope of the WHO prequalification program. The WHO prequalification of medicines is a service provided by WHO to assess the quality, safety, and efficacy of medicinal products to give international procurement agencies the choice of a wide range of quality medicines for bulk purchase for distribution in resource-limited countries.

Susanne Keitel, PhD, is director of the European Directorate for the Quality of Medicines and Healthcare (EDQM) of the Council of Europe in Strasbourg, France. EDQM is also responsible for the European Pharmacopoeia (Ph.Eur.),
.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here